A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

11 Dec 2024 Results presented in the Eisai Co Ltd media release Media Release.
11 Dec 2024 According to Eisai Co Ltd media release, company announced that it has received approval for URECE (Dotinurad) from the National Medical Products Administration in China as a treatment for gout patients with hyperuricemia. the approval is based on the results of this Phase 3 trial.
15 Jun 2024 Results presented at the 25th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com